Transparency Market Research published new market report"Non-Invasive Prenatal Testing (NIPT) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019".The global NIPT market was valued at USD 0.22 billion in 2012 and is expected to grow at a CAGR of 37.6% from 2013 to 2019, to reach an estimated value of USD 3.62 billion in 2019.Non-invasive prenatal testing (NIPT) is used for screening pregnant women at high risk of developing fetal chromosomal aneuploidies such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), and Turner syndrome (monosomy X), and also for fetal sex determination. Browse the report With Full TOC at http://www.transparencymarketresearch.com/noninvasive-prenatal-diagnostics-market.html

1. Transparency Market Research (TMR) provides a range of marketing
and business research solutions designed for your specific needs. From
off-the-shelf syndicated business & market research to made-to-order
custom research, we serve our clients to fulfill their immediate as well
as ongoing research requirements.
Contact Us : State Tower,90 State Street,Suite 700,Albany NY – 12207,United States
Tel: +1-518-618-1030
Email: sales@transparencymarketresearch.com

2. Non-Invasive Prenatal Testing
(NIPT) Market - Global Industry
Analysis, Size, Share, Growth, Trends
and Forecast, 2013 - 2019
Single User
License: US $
4795
Multi User
License: US $
7795
Corporate
User License:
US $ 10795
Single User License
US $ 4795
Multi User License
US $ 7795
Corporate User License
US $ 10795
Buy Now
Request Sample
68
Pages
Report
Published Date : Jan
2014

3. PR : Non-Invasive Prenatal Testing (NIPT) Market Expected to
Reach USD 3.62 Billion Globally in 2019: Transparency Market
Research
Transparency Market Research is Published new Market Report Non-Invasive Prenatal
Testing (NIPT) Market (MaterniT21 PLUS, verifi, Harmony, Panorama, NIFTY,
PrenaTest and BambniTest) - Global Industry Analysis, Size, Share, Growth,
Trends and Forecast, 2013 - 2019," the global NIPT market was valued at USD 0.22
billion in 2012 and is expected to grow at a CAGR of 37.6% from 2013 to 2019, to reach an
estimated value of USD 3.62 billion in 2019.
The market for non-invasive prenatal testing is evolving rapidly due the advantages it offers
over the conventional prenatal screening and diagnostic methods such as maternal serum
screening, nuchal translucency (NT) scan, amniocentesis and chorionic villus sampling
(CVS). These advantages include safety, accuracy, and no risk of miscarriage. An NIPT is a
non-invasive genetic screening test for the common chromosomal abnormalities (trisomy
21, trisomy 18, trisomy 13, monosomy X, etc.) observed in the fetuses of high risk
pregnant women (above the age of 35 years). Owing to its ability to detect the presence of
chromosomal abnormalities in fetuses of pregnant women as early as 9 to 10 weeks of
gestation, the market for non-invasive prenatal testing is witnessing a rapid increase in
demand from all parts of the world.
MaterniT21 PLUS, verifi, Harmony, Panorama, NIFTY, PrenaTest and BambniTest are the
commercially available NIPTs in the market which are based on the direct analysis of cellfree fetal DNA in the maternal blood. In 2012, MaterniT21 (a proprietary product of
Sequenom, Inc.) accounted for the largest share (36.6%) of the global NIPT market in
terms of revenue, owing to the fact that it was the first mover in the market place. During
the forecast period 2013 to 2019, it is likely to lose some of its share due to increasing
market penetration by other aforementioned NIPTs such as Panorama and verifi.
High incidence rate of babies born with certain type of chromosomal abnormalities, growing
trend of child bearing at advanced maternal age and enhanced popularity of NIPT among
gynecologists and high risk pregnant women are some of the major factors anticipated to
drive growth of the NIPT market during the forecast period. Some of the most commonly
detected chromosomal aneuploidies include Down syndrome, Edwards syndrome, Patau
syndrome and monosomy X. On the other hand, ethical and regulatory hurdles are expected
to pose significant challenges before the NIPT market to grow. Various professional
committees across the world believe that the implementation of NIPT and the subsequent
rise in uptake of prenatal testing is likely to increase the incidence of abortions.

4. Therefore, professional groups such as The American College of Obstetricians and
Gynecologists (ACOG), International Society for Prenatal Diagnosis and The Japan Society of
Obstetrics and Gynecology have set up guidelines that limit the use of non-invasive prenatal
testing only to pregnant women at high risk of chromosomal aneuploidies.
Browse the full report with complete TOC at
http://www.transparencymarketresearch.com/noninvasive-prenatal-diagnosticsmarket.html
Geographically, North America was the largest regional market in 2012 with a market share
of 64.5% of the total revenue generated globally, followed by Europe. Almost every
company operating in this market is adopting the same business model of marketing their
tests via alliances with hospitals, diagnostic laboratories and physician offices. The
increasing penetration by test developers in European, Asia-Pacific and Middle-East
countries indicates promising growth in the near future in these markets. Sequenom, Inc.,
Verinata Health, Inc. (now a part of Illumina, Inc.), Ariosa Diagnostics, Natera, Inc., BGI
Health, LifeCodexx and Berry Genomics are the companies engaged in providing noninvasive prenatal tests worldwide.
The global non-invasive prenatal testing market is segmented as follows:
Non-Invasive Prenatal Testing Market, by Test

MaterniT21 PLUS

verifi

Harmony

Panorama

NIFTY

PrenaTest

BambniTest
Non-Invasive Prenatal Testing Market, by Geography

North America

Europe

Asia-Pacific

Rest of the World (RoW)

5. Table of
Content
Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.3.1 Sources
1.3.1.1 Secondary Research
1.3.1.2 Primary Research
1.3.2 Models
Related & Recently Published Reports by Transparency Market Research

Broadcast Switchers Market:
http://www.transparencymarketresearch.com/broadcast-switchersmarket.html

Refrigerated Display Cases (Plug-in and Remote) Market:
http://www.transparencymarketresearch.com/refrigerated-displaycabinets.html

Physical Security (Hardware, Software and Services) Market:
http://www.transparencymarketresearch.com/physical-securitymarket.html

Anti-aging Market: http://www.transparencymarketresearch.com/antiaging-market.html

Teleradiology Market:
http://www.transparencymarketresearch.com/teleradiology-technologyMarket.html

Nanomedicine Market:
http://www.transparencymarketresearch.com/nanomedicine-market.html

6. Chapter 2 Executive Summary
Chapter 3 Global Non-Invasive Prenatal Testing Market Overview
3.1 Introduction
3.2 Major Chromosomal Aneuploidies and their Incidence Rate
3.2.1 Down Syndrome
3.2.2 Edwards Syndrome
3.2.3 Patau Syndrome
3.2.4 Turner Syndrome
3.2.5 Klinefelter Syndrome
3.2.6 Jacobs Syndrome
3.2.7 Triple X Syndrome
3.3 Technological Approach for NIPT
3.4 Market Drivers
3.4.1 High incidence rate of babies born with Down syndrome
3.4.2 Rise in average maternal age
3.4.3 Increasing demand for early and non-invasive fetal testing procedures
3.5 Market Restraints
3.5.1 Regulatory guidelines and ethical hurdles
3.5.2 Limitations of NIPT
3.5.3 Availability of other screening and testing methods
3.6 Market Opportunities
3.6.1 Capitalizing on the potential presented by the emerging markets of Asia
3.7 Porter’s Five Force Analysis for the Global Non-Invasive Prenatal testing Market
3.7.1 Bargaining power of suppliers
3.7.2 Bargaining power of buyers
3.7.1 Threat of substitutes

7. 3.7.2 Threat of new entrants
3.7.3 Competitive rivalry
3.8 Market Attractiveness Analysis: Global Non-Invasive Prenatal Testing Market, by
Geography
Chapter 4 Global Non-Invasive Prenatal Testing Market Revenue, by Test, 2012 2019 (USD Million)
4.1 Overview
4.1.1 Global Non-Invasive Prenatal Testing Market Revenue, by Test, 2012 – 2019 (USD
Million)
4.1.2 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Revenue, by
Test, 2012 & 2019 (Value %)
4.2 MaterniT21 PLUS
4.2.1 Global MaterniT21 PLUS Test Market Revenue, 2012 – 2019 (USD Million)
4.3 Harmony Prenatal Test
4.3.1 Global Harmony Test Market Revenue, 2012 – 2019 (USD Million)
4.4 verifi Prenatal Test
4.4.1 Global verifi Test Market Revenue, 2012 – 2019 (USD Million)
4.5 Panorama Test
4.5.1 Global Panorama Test Market Revenue, 2012 – 2019 (USD Million)
4.6 Noninvasive Fetal Trisomy (NIFTY) Test
4.6.1 Global NIFTY Test Market Revenue, 2012 – 2019 (USD Million)
4.7 BambniTest
4.7.1 Global BambniTest Test Market Revenue, 2012 – 2019 (USD Million)
4.8 PrenaTest
4.8.1 Global PrenaTest Test Market Revenue, 2012 – 2019 (USD Million)

8. Chapter 5 Global Non-Invasive Prenatal Testing Market Revenue, by Geography,
2012 - 2019 (USD Million)
5.1 Overview
5.1.1 Global Non-Invasive Prenatal Testing Market Revenue, by Geography, 2012 2019 (USD Million)
5.1.2 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Revenue, by
Geography, 2012 & 2019 (Value %)
5.2 North America
5.2.1 North America Non-Invasive Prenatal Testing Market Revenue, 2012 - 2019 (USD
Million)
5.3 Europe
5.3.1 Europe Non-Invasive Prenatal Testing Market Revenue, 2012 - 2019 (USD Million)
5.4 Asia-Pacific
5.4.1 Asia-Pacific Non-Invasive Prenatal Testing Market Revenue, 2012 - 2019 (USD
Million)
5.5 Rest of the World (RoW)
5.5.1 Rest of the World (RoW) Non-Invasive Prenatal Testing Market Revenue, 2012 2019 (USD Million)
Chapter 6 Competitive Landscape
6.1 Market Share Analysis, by Key Players, 2012 (%)
Chapter 7 Recommendations
7.1 Focus on improving technology in order to increase the accuracy, reduce the duration of
result generation and price
7.2 Focus on forming alliances with diagnostic service providers in European and Asia-Pacific
countries
7.3 Mergers and acquisitions

9. Chapter 8 Company Profiles
8.1 Ariosa Diagnostics, Inc.
8.1.1 Company Overview
8.1.2 Product Portfolio
8.1.3 Business Strategies
8.1.4 Recent Developments
8.2 Berry Genomics Co., Ltd
8.2.1 Company Overview
8.2.2 Product Portfolio
8.2.3 Business Strategies
8.2.4 Recent Developments
8.3 BGI Health
8.3.1 Company Overview
8.3.2 Product Portfolio
8.3.3 Business Strategies
8.4 LifeCodexx AG
8.4.1 Company Overview
8.4.2 Product Portfolio
8.4.3 Business Strategies
8.4.4 Recent Developments
8.5 Natera, Inc.
8.5.1 Company Overview
8.5.2 Product Portfolio
8.5.3 Business Strategies
8.5.4 Recent Developments
8.6 Sequenom, Inc.
8.6.1 Company Overview

10. 8.6.2 Financial Overview
8.6.3 Product Portfolio
8.6.4 Business Strategies
8.6.5 Recent Developments
8.7 Verinata Health, Inc.
8.7.1 Company Overview
8.7.2 Product Portfolio
8.7.3 Recent Developments
About Us
Transparency Market Research is a global market intelligence company, providing global
business information reports and services. Our exclusive blend of quantitative forecasting
and trends analysis provides forward-looking insight for thousands of decision makers. We
are privileged with highly experienced team of Analysts, Researchers, and Consultants, who
use proprietary data sources and various tools and techniques to gather, and analyze
information.
Our data repository is continuously updated and revised by a team of research experts, so
that it always reflects the latest trends and information. With a broad research and analysis
capability, Transparency Market Research employs rigorous primary and secondary research
techniques in developing distinctive data sets and research material for business reports.
Contact us :
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Web: http://www.transparencymarketresearch.com/